Ukrainian Pharma: challenges and opportunities Pharmaceutical Industry Review, special issue, December 2022
During last 5 years the company invested about UAH 730 M into R&D of new medicines. During this time we launched 63 new brands that strengthened our leadership positions in Ukrainian pharma industry. In 2021 every seventh
pack of medicines on pharmacies’ shelves was produced by Darnitsa*. Due to digital transformation and business processes optimization the company managed to accelerate launch of new
*Data of Proxima Research company **РП UA/19348/01/01. It’s compulsory to read the instruction before taking the medicine.
medicines – the timing was decreased from 30 to 18 months. This enabled Darnitsa to launch 22 new medicines in 2021 in comparison with 10 in 2020. Despite the large scale war during 3 quarters of 2022 pharmaceutical company Darnitsa managed to launch 15 new medicines from anaesthetic, antirheumatic, antihypertensive categories, mucolytics as well as medicines enabling preventivon of thyroid gland diseases during nuclear technological accidents. Nowadays we completely fulfil the plan for R&D of new medicines which was approved for 2022. Before the end of the year we will launch 4 more new medicines. Ukraine is facing new strategic challenges – Darnitsa is aware of and help to answer them. In April 2022, in cooperation with the Ministry of Health of Ukraine and the National Security and Defense Council of Ukraine, we registered a drug to protect the population from radiation – “Potassium Iodide-125- Darnitsa”**. We started its manufacturing within the shortest possible time. We donated 5,25 M doses of the medicine from the first batch to the Ministry of Health free of charge. Since May 2022 it is available in Ukrainian pharmacies. Up to now we manufactured 12 M units of “Potassium Iodide-125- Darnitsa”. Darnitsa has manufacturing facilities able to produce sufficient amount of this medicine for all population of Ukraine. We are able to manufacture 100 M tablets every month. But one should understand that consumption of “Potassium Iodide-125-Darnitsa” may have negative consequences if you don’t follow the prescription. The prophylactic dose of potassium iodide should be taken only after the official radioactive warning from officials or State Emergency Service of Ukraine. During the war we have received the license for manufacturing of Pfizer anti-COVID drugs and mRNA vaccines within the WHO program.
40 BACK TO CONTENTS
www.promoboz.com
www.promoboz.com |
www.cphem.com
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60 |
Page 61 |
Page 62 |
Page 63 |
Page 64 |
Page 65 |
Page 66 |
Page 67 |
Page 68
